The Impact of Opioids in Coronary Heart Disease

Overview

In this study, the risk of opioid medications on coronary heart disease in adults is investigated. Patients with the necessity of a coronary angiography and control patients with a non-cardiac disease of the same hospital are inquired with a standardized questionnaire about demographic and clinical risk factors for heart attack. An impact of opioid medications on coronary heart disease is hypothesised (MIOP). In addition, all patients with coronary angiography should be consulted twice (after 3 and 6 months) to find out how many of these patients have developed a refractory angina pectoris (TRAPS).

Full Title of Study: “Evaluation of Past Medications in Patients With Coronary Heart Disease and Patients Hospitalized for a Non-cardiac Reason”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 2017

Arms, Groups and Cohorts

  • Patients with coronary heart disease
    • coronary angiography with finding coronary heart disease currently no cancer 40 years or older
  • control patients
    • coronary angiography with exclusion coronary heart disease or other patients with non-cardiac diseases currently no cancer 40 years or older

Clinical Trial Outcome Measures

Primary Measures

  • Number of patients with opioid treatment (WHO II/ WHO III) within the last 10 years before present hospitalization, Interview with standardized CRF
    • Time Frame: 20 minutes
    • Standardized assessment of opioid medications taken before hospital admission to evaluate the impact of opioids in coronary heart disease. Exact doses, substances and intake habits are inquired.
  • Number of patients with refractory angina pectoris, Interview with standardized CRF
    • Time Frame: 30 minutes
    • Standardized assessment of angina pectoris symptoms and treatments to evaluate a refractory angina pectoris. Changes of their medications are inquired twice.

Participating in This Clinical Trial

Inclusion Criteria

  • 40 years or older – written informed consent Exclusion Criteria:

  • currently cancer – cognitive limitations

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ruhr University of Bochum
  • Collaborator
    • Mundipharma Research GmbH & Co KG
  • Provider of Information About this Clinical Study
    • Principal Investigator: Christoph Maier, Prof. Dr., Prof., Dr. – Ruhr University of Bochum

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.